{"denoms":[{"counts":[{"groupId":"BG000","value":"302"},{"groupId":"BG001","value":"153"},{"groupId":"BG002","value":"455"}],"units":"Participants"}],"groups":[{"description":"Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.","id":"BG000","title":"Pomalidomide Plus Low-Dose Dexamethasone"},{"description":"Participants received 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle until disease progression.","id":"BG001","title":"High-Dose Dexamethasone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.33","value":"63.6"},{"groupId":"BG001","spread":"9.56","value":"63.7"},{"groupId":"BG002","spread":"9.40","value":"63.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"278"},{"groupId":"BG001","value":"141"},{"groupId":"BG002","value":"419"}],"title":"≤ 75 Years Old"},{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"36"}],"title":"> 75 Years Old"}]}],"description":"Stratification Factor 1","paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"121"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"187"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"181"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"268"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"41"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"228"},{"groupId":"BG001","value":"104"},{"groupId":"BG002","value":"332"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"82"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"244"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"357"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"83"}],"title":"Not collected"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"302"},{"groupId":"BG001","value":"153"},{"groupId":"BG002","value":"455"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Participants with Prior Anti-Myeloma (MM) Therapies","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"4.02","value":"6.2"},{"groupId":"BG001","spread":"3.63","value":"6.5"},{"groupId":"BG002","spread":"3.89","value":"6.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Time from First Pathologic Diagnosis","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"249"},{"groupId":"BG001","value":"125"},{"groupId":"BG002","value":"374"}],"title":"Disease Population Group 1"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"13"}],"title":"Disease Population Group 2"},{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"68"}],"title":"Disease Population Group 3"}]}],"description":"Disease Population Group 1 is defined as refractory patients who have progressed on or within 60 days of both lenalidomide and bortezomib based treatments. Disease Population Group 2 is defined as relapsed and refractory patients who achieved at least a partial response (PR) and progressed within 6 months after stopping treatment with lenalidomide and/or bortezomib. Disease Population Group 3 is defined as refractory/intolerant patients who developed intolerance/toxicity after a minimum of 2 cycles of bortezomib.","paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification Factor 2: Disease Population","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"25"}],"title":"2 Prior Anti-MM Therapies"},{"measurements":[{"groupId":"BG000","value":"285"},{"groupId":"BG001","value":"145"},{"groupId":"BG002","value":"430"}],"title":"> 2 Prior Anti-MM Therapies"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification Factor 3: Number of Prior Anti-MM Therapies","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"117"}],"title":"Stage I"},{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"171"}],"title":"Stage II"},{"measurements":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"145"}],"title":"Stage III"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"22"}],"title":"Missing"}]}],"description":"The International Staging System divides myeloma into 3 stages based only on the serum beta-2 microglobulin and serum albumin levels. Stage I: Serum beta-2 microglobulin is less than 3.5 (mg/L) and the albumin level is above 3.5 (g/L); Stage II: Neither stage I or III, meaning that either: ◾ The beta-2 microglobulin level is between 3.5 and 5.5 (with any albumin level), OR ◾ The albumin is below 3.5 while the beta-2 microglobulin is less than 3.5 Stage III: Serum beta-2 microglobulin is greater than 5.5.","paramType":"COUNT_OF_PARTICIPANTS","title":"Multiple Myeloma Stage before Study Entry","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-treat population (all participants who were randomized, regardless of whether they received study treatment or not)"}